Synageva BioPharma announced an expansion of its previous pharma partners collaboration with Mitsubishi Tanabe Pharma to develop a second protein therapeutic for an undisclosed orphan disease using Synageva’s product development capabilities and proprietary protein expression platform.
Terms of the expanded pharma partners collaboration:
Under the terms of the pharma partners agreement, Mitsubishi Tanabe Pharma will make an upfront payment of $9 million.
Synageva will receive reimbursement for development costs, potential future development and commercial milestone payments, as well as royalties from potential product revenue.
See further details at Current Agreements
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Mitsubishi Tanabe
Report: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity